Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3720798 | 0.90 | TDP1 (0.58) | TDP1SIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL19554174 | 0.86 | TDP1 (0.57) | TDP1SIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL10784720 | 0.85 | TDP1 (0.70) | TDP1SIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL268414 | 0.85 | TDP1 (0.62) | TDP1SIRT6AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL8878937 | 0.82 | TDP1 (0.60) | TDP1SIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL28059438 | 0.82 | ALDH1A1 (0.53) | AKR1C3AKR1C2SMN1; SMN2LMNAHPGD | |
| SCHEMBL3471731 | 0.81 | POLB (0.51) | TDP1SIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL18260661 | 0.80 | TDP1 (0.57) | TDP1SIRT6AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL2724028 | 0.79 | TDP1 (0.62) | TDP1SIRT6AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL3512673 | 0.79 | TDP1 (0.62) | TDP1SIRT6SMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-28 | — | — | US | disclosed |
| EP-1614676-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | SLC10A6, SLC7A1, SLC10A1 | TDP1 4744/4885SIRT6 1904/4885PDGFRB 500/4885 |
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | SLC34A1, SLC34A2, SLC20A2 | TDP1 4604/4885SIRT6 2238/4885PDGFRB 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.